The device is at the core of the BRAVO trial, which evaluates signals to control complex devices for motor and speech in adults who have been severely affected by neurological disorders.
Thermo Fisher Scientific has launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as it engages in more large-scale cohort studies and clinical research.
Through its OrbNet platform, Entos has already forged various partnerships with investors and leaders in the pharmaceuticals, materials, and chemicals industries.
The license and collaboration agreement center on orelabrutinib, an oral small molecule BTKi characterized by its high selectivity and the ability to cross the blood-brain barrier.
A new study has found potential in a novel gene therapy method to help children born with the rare genetic and neurodegenerative disorder, AADC deficiency.
Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.
The company said that it values the FDA’s feedback and is happy that the agency has accepted its request to provide insights on its Hepatitis B development program.
Sparx Therapeutics is expanding its operations into Yangzhou, China, with the imminent construction of a 1.2 million square foot facility for its commercial production.
The study, which compared the same treatment combination to pomalidomide plus dexamethasone covered 495 patients from over a hundred hospitals in 21 countries.
The company said it would halt activities and focus its resources and time on liver and obesity research following “disappointing” results of its intranasal COVID-19 vaccine.
Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates.
